Autopsy report · NCT04335305

Checkpoint Blockade in COVID-19 Pandemic

“Recruitment issues”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 2 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

MedSIR

Sponsor type

University, hospital or other

Conditions

COVID-19; Pneumonia, Viral

Interventions

Tocilizumab; Pembrolizumab (MK-3475)

Participants

12

Sites

7

Countries

Spain

Trials that died the same way

• Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
  “Issues with recruitment.” (97% match in meaning)
• Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus
  “Recruitment problems” (95% match in meaning)
• Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer
  “Problems of recruitment” (94% match in meaning)
• Burden of Obstructive Sleep Apnea in Stroke (BOSAST)
  “problems with recruitment” (93% match in meaning)
• Robotic Decompression of the Pudendal Nerve in Pudendal Neuralgia
  “recruitments difficulties” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.